文献速递肝病

他汀类药物对慢性肝病患者肝纤维化进展率、肝功能失代偿及死亡率的有益影响:系统评价与荟萃分析

Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Gastroenterol · 2017-06-06

该系统评价与荟萃分析纳入10项研究(1项随机对照试验和9项观察性研究)共259,453例患者(他汀使用者54,441例,非使用者205,012例),评估他汀对慢性肝病结局的影响。结果显示他汀使用与肝纤维化进展(合并HR 0.49,95%CI 0.39-0.62)、肝硬化失代偿(合并HR 0.54,95%CI 0.46-0.65)及全因死亡(观察性研究合并HR 0.67,95%CI 0.46-0.98;随机对照试验HR 0.39,95%CI 0.15-0.99)风险降低相关,但证据质量低,需进一步研究后方可常规推荐他汀。

要点

  • 他汀使用与肝纤维化进展风险降低相关(合并HR 0.49,95%CI 0.39-0.62)。
  • 他汀使用与肝硬化失代偿风险降低相关(合并HR 0.54,95%CI 0.46-0.65)。
  • 他汀使用与全因死亡风险降低相关,但证据质量低,需进一步研究。

核心结论

  • 他汀可能延缓肝纤维化进展、可能预防肝硬化失代偿、可能降低慢性肝病患者全因死亡率。
  • 由于证据质量(确定性)低,在常规推荐他汀之前需进一步研究。

研究设计与样本

  • 系统评价与荟萃分析,检索多个数据库自建库至2016年10月17日,纳入比较研究评估他汀在慢性肝病中的作用。
  • 共纳入10项研究(1项随机对照试验和9项观察性研究),259,453例患者(他汀使用者54,441例,非使用者205,012例)。
  • 采用随机效应模型合并分析调整后风险比(HR),并根据肝纤维化进展检测方法和研究质量进行亚组分析。

主要发现

  • 肝纤维化进展的合并HR为0.49(95%CI 0.39-0.62)。
  • 采用ICD-9编码加第二种方法检测肝硬化的研究亚组,合并HR为0.58(95%CI 0.51-0.65);仅采用ICD-9编码的研究亚组,合并HR为0.36(95%CI 0.29-0.44)。
  • 丙型肝炎病毒感染患者肝纤维化进展的合并HR为0.52(95%CI 0.37-0.73)。
  • 肝硬化失代偿的合并HR为0.54(95%CI 0.46-0.65)。
  • 基于观察性研究的死亡合并HR为0.67(95%CI 0.46-0.98);随机对照试验中HR为0.39(95%CI 0.15-0.99)。

临床怎么用

  • 他汀可能延缓肝纤维化进展、可能预防肝硬化失代偿、可能降低慢性肝病患者全因死亡率(作者结论)。
  • 由于证据质量低,在常规推荐他汀之前需进一步研究(作者结论)。

局限性

  • 大多数纳入研究为回顾性研究,且受残余混杂因素限制。
  • 这些关联的证据质量低。
  • 在常规推荐他汀之前需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Statins may improve outcomes in patients with chronic liver disease (CLD). We conducted a systematic review and meta-analysis to evaluate the impact of statins in the setting of CLD. METHODS: We searched several databases from inception to 17 October 2016 to identify comparative studies evaluating the role of statins in CLD. Outcomes of interest were the associations between statin use and progression of fibrosis, development of hepatic decompensation in cirrhosis, and mortality in CLD. Adjusted hazard ratios (HRs) were pooled and analyzed using a random effects model. Subgroup analyses were performed based on the method of detection for progression of hepatic fibrosis and quality of studies. RESULTS: We included 10 studies (1 randomized controlled trial and 9 observational) with 259,453 patients (54,441 statin users and 205,012 nonusers). For progression of hepatic fibrosis, pooled HR (95% confidence interval) was 0.49 (0.39-0.62). On subgroup analysis of studies using ICD-9 (The International Classification of Diseases, Ninth Revision) coding and a second method to detect cirrhosis, pooled HR was 0.58 (0.51-0.65); pooled HR for studies using ICD-9 coding only was 0.36 (0.29-0.44). For progression of fibrosis in patients with hepatitis C virus (HCV) infection, pooled HR was 0.52 (0.37-0.73). For hepatic decompensation in cirrhosis, pooled HR was 0.54 (0.46-0.65). For mortality, pooled HR based on observational studies was 0.67 (0.46-0.98); in the randomized controlled trial, HR was 0.39 (0.15-0.99). However, the quality of evidence for these associations is low as most included studies were retrospective in nature and limited by residual confounding. CONCLUSIONS: Statins may retard the progression of hepatic fibrosis, may prevent hepatic decompensation in cirrhosis, and may reduce all-cause mortality in patients with CLD. As the quality (certainty) of evidence is low, further studies are needed before statins can be routinely recommended.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kamal S, Khan MA, Seth A, et al. Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017. PMID: 28585556. doi:10.1038/ajg.2017.170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。